Semaglutide and 50-pound weight loss: separating real results from TikTok hype

What did @megannicolle87 actually say?

Almost nothing, technically. The entire transcript is a single lyric loop: "I took the drugs and the drugs are working." That's it. No dosage claims, no before-and-after timeline, no side effect disclosure. The video's actual informational content lives entirely in the caption, which reports 50 lbs lost on semaglutide and stamps it with "no regrets."

That distinction matters. A sung lyric is not a medical claim, but the caption framing absolutely is. Together they imply semaglutide produced a 50 lb weight loss that was worth the cost and came without downsides worth mentioning. That composite message is what needs scrutinizing, not the song choice.

To @megannicolle87's credit, she doesn't prescribe anything, invent a mechanism, or claim a cure. She shares a personal outcome. That's a lower-risk format than the TikTok weight loss genre usually delivers.

Does the science back this up?

A 50 lb loss on semaglutide is plausible and within the documented range, but it lands at the higher end. The landmark STEP 1 trial showed it, and subsequent real-world data roughly confirm the range.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) randomized 1,961 adults with obesity to 2.4 mg weekly semaglutide or placebo. At 68 weeks, the semaglutide group lost a mean of 14.9% of body weight versus 2.4% for placebo. For someone starting at roughly 250 lbs, 14.9% works out to about 37 lbs. Hitting 50 lbs would require either a higher starting weight, a longer treatment duration than 68 weeks, or being among the higher responders in the distribution. All of those are real possibilities.

A 2023 real-world analysis by Ghusn et al. in Obesity Pillars tracked 175 patients at Mayo Clinic and found mean weight loss of 5.9% at 3 months, 10.9% at 6 months, and 15.3% at 12 months, with significant individual variation. So 50 lbs over a longer haul, as the hashtag "longhaul" suggests, is scientifically consistent with what we know.

What did they get wrong (or right)?

"No regrets" is the claim that deserves the most skepticism, and it's also the one that 314,000 viewers are probably absorbing most uncritically. Semaglutide has a well-documented side effect profile that affects a substantial portion of users.

In STEP 1, 74.2% of participants in the semaglutide group reported gastrointestinal adverse events, compared to 47.9% in the placebo group. Nausea was the most common, reported by 44% of the treatment group. Serious adverse events occurred in 9.8% of the semaglutide group. These aren't rare edge cases. They're majority-frequency outcomes in the trial population.

There's also the discontinuation question. In STEP 1, 7.0% of the semaglutide group discontinued due to adverse events. Real-world discontinuation rates are higher. A 2023 study by Wilkinson et al. in Annals of Internal Medicine found that among commercially insured patients, only about 44% were still on GLP-1 medications at 12 months.

None of this means @megannicolle87's experience was fabricated or atypical among successful completers. It means "no regrets" describes one slice of the outcome distribution, not the full picture.

What should you actually know?

Semaglutide produces real, clinically significant weight loss in a meaningful subset of patients, and the evidence base is stronger than for almost any prior weight loss pharmacotherapy. That's worth saying plainly.

But the drug comes with real tradeoffs. Cost is not trivial: brand-name Wegovy lists above $1,300 per month in the US without insurance coverage, which remains inconsistent. The "worth every penny" framing assumes a financial reality that many patients don't have.

Weight regain after stopping is also documented. A follow-up to STEP 1 published by Wilding et al. in 2022 in Diabetes, Obesity and Metabolism found that participants regained two-thirds of their lost weight within one year of stopping the medication. This is not a flaw in the drug so much as a feature of treating a chronic condition, but it reframes "worth every penny" as an ongoing cost commitment, not a one-time investment.

Anyone seeing this video and considering semaglutide should speak with a licensed clinician who can assess cardiovascular history, thyroid risk factors, and medication interactions. TikTok success stories, however genuine, are not a substitute for that evaluation.